Frozen plasma, buffy coat, FFPE blocks and slides
Research

Chris Diehnelt, Founder and CEO at Robust Diagnostics, presents peptide microarray research at AMP 2024

Nov 23, 2024

An investigation into frameshift and wild-type microarray reactivity in colorectal cancer and healthy patients, done in collaboration with Reference Medicine.

‍Originally presented at the Association of Molecular Pathology Annual Conference 2024.

  • Poster presentation: November 23rd, 2024 at 9:15am - 10:15am
Download

Subscribe for updates

No spam — just the news you want: product launches, process improvements, and discounts on our already great pricing.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Media Contact

For more information or to schedule an interview, please contact:
Jen Ringler
ReadHealthy Communications
jringler@readhealthy.net

Share this post

More research
Research
Dec 11, 2024

Reference Medicine presents findings of MammaPrint® recurrence risk stratification in early-stage breast carcinomas at SABCS 2024

Read article
Research
Nov 22, 2024

Chris Diehnelt, Founder and CEO at Robust Diagnostics, presents Streck tube research at AMP 2024

Read article
Research
Nov 14, 2024

Reference Medicine presents findings on the quality of bio-banked tissue – blood matched samples at AACR Liquid Biopsy Conference

Read article
See all
Process
Products
Pricing
Inventory

Subscribe to our newsletter

No spam — just the news you want: product launches, process improvements, and discounts on our already great pricing.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
 | 
© 2024 Reference Medicine. All rights reserved